VRDN
Viridian Therapeutics Inc.
Company Overview
| Mkt Cap | $1.59B | Price | $17.00 |
| Volume | 1.49M | Change | -1.39% |
| P/E Ratio | -4.6 | Open | $18.00 |
| Revenue | $70.8M | Prev Close | $17.24 |
| Net Income | $-342.6M | 52W Range | $13.18 - $34.29 |
| Div Yield | N/A | Target | $33.88 |
| Overall | 36 | Value | 60 |
| Quality | 23 | Technical | 27 |
No chart data available
About Viridian Therapeutics Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Latest News
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
Viridian Therapeutics Raises $359 Million in Offerings
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)
Analysts Are Bullish on These Healthcare Stocks: Biodesix (BDSX), Viridian Therapeutics (VRDN)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRDN | $17.00 | -1.4% | 1.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viridian Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW